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Abstract
Extensive clinical experience has shown that systemic interleukin (IL)-2 administration can induce
complete or partial regression of renal cell cancer (RCC) metastases in 15 to 20 % of patients. Since
IL-2 has no direct anti-cancer effects, it is believed that cancer regression is mediated either by a
direct modulation of immune cell effector functions or through the mediation of soluble factors
released as a result of IL-2 administration.
We previously observed that transcriptional and protein changes induced by systemic IL-2
administration affect predominantly mononuclear phagocytes with little effect, particularly within
the tumor microenvironment, on T cell activation, localization and proliferation. It further
appeared that mononuclear phagocyte activation could be best explained by the indirect mediation
of a secondary release of cytokines by IL-2 responsive cells either in the circulation or in peripheral
tissues.
To better characterize the cytokine outburst that follows systemic IL-2 administration we followed
the serum levels of 68 soluble factors in ten patients with RCC undergoing high dose (720,000 IU/
kg intravenously every 8 hours) IL-2 therapy. Serum was collected before therapy, 3 hours after
the 1st and 4th dose and assayed on a multiplexed protein array platform. This study demonstrated
that 1) the serum concentration of more than half the soluble factors studied changed significantly
during therapy; 2) changes became more dramatic with increasing doses; 3) subclasses of soluble
factors displayed different kinetics and 4) cytokine patterns varied quantitatively among patients.
This study shows that the cytokine storm that follows systemic IL-2 administration is complex and
far-reaching inclusive of soluble factors with disparate, partly redundant and partly contrasting
effects on immune function. Therefore comparing in parallel large number of soluble factors, it sets
a comprehensive foundation for further elucidation of "cytokine storm" in larger patient pools.
Based on this analysis, we propose a prospective collection of serum samples in a larger cohort of
patients undergoing IL-2 administration with the purpose of discerning patterns predictive of
clinical outcome and toxicity.
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Background
Interleukin-2 (IL-2) has been extensively used as a single
agent for anti-cancer immunotherapy [1,2]. This immune
modulatory cytokine can induce long term cures and has
been approved by the Food and Drug Administration for
standard therapy of metastatic melanoma and renal cell
cancer. In addition, it appears that systemic IL-2 adminis-
tration may increase the frequency of tumor regressions
mediated by tumor antigen-specific immunization [3]
Although, it has been postulated that IL-2 acts through the
in vivo expansion and activation of cytotoxic T lym-
phocytes [1] and/or the promotion of their migration
within target tissues [3], it is likely that at the pharmaco-
logic doses used therapeutically IL-2 has broader
immune/pro-inflammatory effects [4,5]. Thus, the mech-
anism(s) through which systemic IL-2 administration
mediates cancer regression remains unknown. It is also
unknown whether the substantial toxicity associated with
IL-2 administration (that limits its therapeutic usefulness)
[6] is mediated through pathways common or distinct
from those mediating its anti-cancer effects [7]. It has
been observed that hematological toxicity induced by IL-
2 (thrombocytopenia and lymphopenia) is associated
with increased frequency of clinical responses [8]. In addi-
tion, reversal of IL-2-induced toxicity by corticosteroid or
anti-TNF-α antibodies blunts its therapeutic effects sug-
gesting a proinflammatory nature for this association
[9,10]. Yet, these and other associations between thera-
peutic and toxic effects are weak and inconclusive and in
all probability different pathways may mediate the two
phenomena. Obviously, the ability to segregate the anti-
cancer effects of IL-2 in target tissues from its systemic
toxic effects may be central for the development of
improved anti-cancer therapies [11].
We have recently analyzed changes induced by the sys-
temic administration of IL-2 on the transcriptional profile
of circulating mononuclear cells and melanoma metas-
tases [12]. This was done by comparing samples obtained
before therapy and three hours after IL-2 administration,
a time point found to be most informative based on pre-
liminary time course studies. Samples were serially
obtained through blood draws and fine needle aspirates
of melanoma metastases following a previously validated
RNA amplification procedure [13]. This study suggested
that the systemic effects of IL-2 administration diverged
from those identifiable within the tumor microenviron-
ment since in the latter they seemed primarily restricted to
the activation of mononuclear phagocytes. In fact, sys-
temic IL-2 administration had very little direct effects on
lymphocyte activation or migration to the tumor site, nor
had direct effects on the survival of tumor cells. More spe-
cifically, it appeared that IL-2 induced activation of resi-
dent mononuclear phagocytes into mature antigen
presenting cells. In addition IL-2 induced activation of
cytolytic mechanisms and a massive production of
chemo-attractants that could secondarily recruit other
immune cells. In addition, the hypothesis that the direct
or indirect effects of IL-2 in the target organ are mediated
through mononuclear phagocyte activation is in line with
the recently reported observation that macrophage activa-
tion by IL-2 is essential for tumor regression [14].
In vitro testing failed to identify IL-2 as the direct agonist
responsible for the activation of mononuclear macro-
phages (unpublished observation) suggesting that a
down-stream cascade of immune modulators produced
by IL-2-responsive cells in vivo might be the principal
mediator of the effect of this cytokine on the tumor micro-
environment. Since it is unlikely that IL-2 directly medi-
ates all of the effects observed after its systemic
administration, we hypothesized that the changes in the
transcriptional program of melanoma metastases were
most likely resulting from an array of soluble factors sec-
ondarily produced by IL-2 receptor-bearing immune cells.
Indeed, a preliminary in vitro analysis of supernatants
from cultures of circulating mononuclear cells exposed to
IL-2 revealed an intense production of a broad array of
cytokines and other soluble factors [15].
The cytokine cascade or cytokine storm induced by sys-
temic IL-2 administration has been extensively reported in
the past and attempts have been made to associate indi-
vidual parameters with biological effects [16,-19]. How-
ever, these studies were limited by the number of
cytokines tested whose selection was based on an edu-
cated guess of their relevance to immune modulation.
Recent advances in high-throughput analysis of gene and
protein expression allow, however, a global and unbiased
overview of complex biological processes adding novel
dimensions to the study of this problem. Here we studied
the serum levels of 68 soluble factors including cytokines,
chemokines, growth factors, soluble receptors and metal-
loproteinases in patients with RCC undergoing systemic
IL-2 therapy. The 68 soluble factors were assembled in a
protein array platform (Searchlight™, Boston, MA) with-
out predetermined bias except for their known or sus-
pected relevance to immune phenomena. This was done
with two main purposes: the first was to attain a general
estimate of the ratio of biologically active factors induced
by systemic IL-2 administration out of a pool of randomly
chosen reagents. This parameter yields a rough estimate of
the complexity and lack of specificity of systemic IL-2
treatment. The second was to provide a map of cytokine
secretion patterns relevant to clinical IL-2 administration
that could help forecast its toxic or beneficial effects in
future prospective studies.Journal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/17
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The results suggested that 1) the serum concentration of
more than half the soluble factors studied changed signif-
icantly during therapy; 2) changes became more dramatic
with increasing doses; 3) subclasses of soluble factors dis-
played different kinetics and 4) cytokine patterns varied
quantitatively among patients.
Results and Discussion
Serum was collected from 16 patients (Table 1 and Table
2). From 15 patients, samples could be obtained before
treatment and 3 hours after the 1st dose. However, in only
10 patients could the pre-determined collection be com-
pleted by obtaining serum before therapy and 3 hours
after the 1st and 4th dose of IL-2. Time points of serum col-
lection were selected based on previous experience sug-
gesting incremental effects of IL-2 administration with
Table 1: Characteristics of the patients enrolled in the study
Patient # Sampling: pre, post 
dose#
Course/ Cycle of Sampling Response Biological Response # of doses
p1 pre, post 1 c1c2 SD 2C NR 3
p2 pre, post 1, post 4 c3c1 SD 2C NR 8
p3 pre, post 1, post 5 c3c1 PR 1C CR 3C BR 5
p4 pre, post 1, post 4 c2c1 PR 1C SD 2C PD BR 7
p5 pre, post 1, post 4 c1c2 SD 1C PD 2C NR 6
p6 pre, post 1 c1c2 PR 2C PD 3C BR 4
p7 pre, post 1 c2c1 SD 1C NR 4
p8 pre c1c1 PD 1C NR 8
p9 pre, post 1, post 4 c1c1 PD 1C NR 7
p10 pre, post 1 c1c2 MR 1C BR 7
p11 pre, post 1 c3c2 SD 1C PR 3C NR 3
p12 pre, post 1, post 4 c1c1 SD NR 8
p13 pre, post 1, post 4 c1c1 PD 1C NR 7
p14 pre, post 1, post 4 c2c1 MR 1C BR 8
p15 pre, post 1, post 4 c1c1 MR 1C BR 7
p16 pre, post 1, post 4 c1c1 PD NR 9
C = course; CR = complete response; SD = stable disease; PR = partial response; MR = mixed response; PD = progressive disease; BR Biological 
response = CR+PR+MR; NR = Non responder = PD+SD
Table 2: Toxicity evaluation in the 16 patients with RCC enrolled in this study
Patient # Age yr Doses Hemoglobin WBC count Platelet Count Bilirubin SGOT Creatinine
p1 41 3 grade 2 * * * * *
p2 56 8 * * grade 1 * * *
p3 53 5 grade 1 * * * * *
p4 54 7 * * grade 1 grade 1 grade 1 grade 1
p5 58 6 grade 2 grade 2 grade 2 grade 3 grade 1 grade 3
p6 47 4 grade 1 * * * * *
p7 54 4 * * * * * grade 2
p8 41 8 grade 1 * * grade 2 grade 1 *
p9 44 7 * * * * grade 1 *
p10 36 7 * * * * * *
p11 60 3 * * * * * *
p12 45 8 * * grade 1 * grade 1 grade 2
p13 70 7 * * * grade 1 grade 1 *
p14 36 8 * grade 1 grade 3 * * *
p15 66 7 * * * * grade 3 *
p16 56 9 * * * * grade 2 *
Toxicity grade is based on the CMC common toxicity criteriaJournal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/17
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increasing doses [12]. It was felt the four doses repre-
sented a reasonable midpoint of IL-2 therapy that could
be achieved in most patients before interruption of treat-
ment due to limiting toxicity. Serum collections were
obtained 3 hours after IL-2 administration because it is
around this time that most of the systemic signs of IL-2
administration are apparent suggesting that the highest
levels of soluble factors are reached around that time
point. Serum was immediately separated to avoid protein
degradation and stored frozen. All serum samples were
thawed simultaneously at the completion of the study and
immediately tested for the presence of 68 soluble factors
(including chemokines, cytokines, soluble cytokine recep-
tors and cell surface molecules) using Searchlight™ arrays.
Cytokines whose concentration in the present conditions
was consistently below the threshold of detection of the
assay (LIF, IFNα, GM-CSF, IL-1α, IL-1β, IL-9, IL-12p70, IL-
13) were excluded from the analysis because we could not
rule out that significant changes may have occurred with
treatment that could not be detected due to the limit of
the assay sensitivity. In addition, we excluded IL-2 because
it was impossible to distinguish the endogenous levels
produced by IL-2 stimulated cells from the circulating
exogenously administered recombinant IL-2. The serum
concentration of 61 % of evaluable factors changed signif-
icantly after one dose of IL-2 (36/59) (Table 3). Similarly,
56 % of the evaluable soluble factors (33/59) increased
significantly in concentration after 1 dose of IL-2 in the 10
patients who completed the study (Table 4). After four
doses, the concentration of the majority of soluble factors
Table 3: Soluble factor (pg/ml) concentrations in the serum of 15 patients enrolled in the study (only factors that demonstrated 
significant changes in concentration after the 1st dose compared with before therapy are shown)
Soluble Factor Average before IL-2 STD error before Average after 1 dose STD error after 1 dose p value before vs. after I dose Bonferroni 
correction
IL2* 0 0 3269 841 0.00126 0.07409
TNFR2 3197 222 6215 462 0.00000 0.00001
MMP9 246408 29501 764715 53413 0.00000 0.00008
TNFR1 1659 92 5217 568 0.00000 0.00024
IFNγ 152 17 235 19 0.00000 0.00027
IP10 152 13 2006 267 0.00001 0.00030
MIP3b 151 12 421 45 0.00001 0.00040
MCP2 36 6 1776 261 0.00001 0.00045
MIP1b 525 137 35905 5761 0.00002 0.00100
MMP8 1502 321 3977 537 0.00002 0.00109
SDF1b 75 16 836 137 0.00005 0.00322
Lymph 142 20 338 43 0.00007 0.00407
IL7 3 1 10 2 0.00008 0.00477
IL5 1 1 9 2 0.00012 0.00691
MCP3 12 1 23 3 0.00020 0.01172
I309 22 4 73 12 0.00026 0.01547
E-Selectin 111526 5901 127683 5461 0.00030 0.01753
IL15 1 1 6 1 0.00038 0.02261
Eotaxin 130 16 401 65 0.00047 0.02757
ITAC 31 3 139 25 0.00056 0.03314
MIP1a 3000 111 3228 104 0.00102 0.06033
Gro-A 297 95 1848 388 0.00104 0.06121
Angio2 467 58 671 71 0.00107 0.06330
IL6 61 13 1092 265 0.00112 0.06589
VegF 1112 139 1498 132 0.00130 0.07661
MCP1 1327 248 124449 32058 0.00136 0.08025
MIG 262 35 933 178 0.00262 0.15480
IL8 65 4 800 211 0.00278 0.16379
IL4 0 0 4 1 0.00422 0.24896
TNFa 539 48 640 50 0.00719 0.42432
TARC 282 47 520 88 0.00939 0.55398
MIP3a 17 3 827 291 0.01195 0.70484
IL6R 24605 1759 27935 2652 0.01393 0.82204
IL10 2 1 41 15 0.01517 0.89505
MDC 605 77 661 74 0.03338 1.96915
MMP10 1440 148 1645 147 0.04876 2.87674
MMP1 13937 1775 16437 1602 0.05007 2.95398
Soluble Factors (pg/ml) present in the serum of patients undergoing high dose IL-2 immunotherapy were averaged before and after 1 dose of IL-2. 
A paired 2-tailed student t test was used to assess significance with an arbitrary cutoff of p= 0.05. Bonferroni's correction was applied to the data 
set by correcting for a total of 59 soluble factors (IL-2 was not factored in); IL-2 levels were included as internal control (*) since these values 
reflect in part administered human recombinant IL-2.Journal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/17
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studied (76%; 45/59) increased significantly (Table 5).
Interestingly, the serum level of 59 % (35/59) of the eval-
uable soluble factors changes significantly between the 1st
and after 4th dose (Table 6). While the serum levels of
most soluble factors increased progressively during the 24
hours that spanned between the first and the fourth dose
a smaller group including MCP-2, MIP-1β, MCP-1, NAP-
2, IL-6R and Rantes decreased in concentration between
the first and the fourth dose. Two factors, MMP-3 and Exo-
dus-2 decreased 3 hours after the first dose but increased
noticeably after the 4th. Although the results presented in
this study are exploratory and fewer cytokine changes
maintained significance after correcting the p2-value for
the number of tests according to Bonferroni's method
[20], it is likely that the changes observed are representa-
tive of true biological behavior of these factors in response
to systemic IL-2 administration and a more powerful
study will confirm these results by allowing a higher level
of significance.
We then classified the various factors according to their
pattern of expression in response to IL-2 by applying
unsupervised hierarchical clustering [21]. We limited this
analysis to the 47 cytokines whose concentration levels
were significantly altered after the 4th dose (Figure 1).
Hierarchical clustering ranks experiments according to
Table 4: Soluble factor (pg/ml) concentrations in the serum of 10 patients who completed the study (only factors that demonstrated 
significant changes in concentration after the 1st dose compared with before therapy are shown)
Soluble Factor Average before 
IL-2
STD error 
before IL-2
Average after 1 
dose
STD error after 
1 dose
p value before 
vs. after 1 dose
Bonferroni 
Correction
IL2* 0 0 3668 1178 0.00948 0.55953
TNFR1 1641 112 4702 512 0.00005 0.00292
MMP8 1187 455 3340 500 0.00008 0.00486
TNFR2 3195 259 6014 628 0.00010 0.00588
MCP1 984 227 81270 13486 0.00013 0.00787
IP10 146 18 1571 273 0.00047 0.02778
MCP2 32 9 1500 291 0.00050 0.02950
MMP9 233004 43617 736428 76301 0.00051 0.02984
I309 18 4 52 8 0.00057 0.03372
IFNγ 149 21 222 25 0.00059 0.03477
IL5 00820 . 0 0 0 9 4 0 . 0 5 5 6 3
MIP1b 512 205 30149 6560 0.00097 0.05714
MIP3b 142 17 347 51 0.00108 0.06345
VegF 865 131 1392 181 0.00175 0.10307
IL7 2 1 10 2 0.00228 0.13444
IL15 00620 . 0 0 3 0 2 0 . 1 7 8 3 4
E-Selectin 106029 5703 118981 5972 0.00351 0.20688
SDF1b 62 21 646 154 0.00372 0.21974
Lymph 111 22 259 39 0.00400 0.23580
IL6 50 5 747 201 0.00521 0.30754
MCP3 10 1 17 2 0.00616 0.36333
MMP1 12912 2478 17411 2235 0.00686 0.40490
Eotaxin 115 22 318 65 0.00762 0.44948
MIP1a 2952 143 3215 141 0.00790 0.46638
Angio2 494 78 655 101 0.01068 0.63039
MCP4 84 19 264 71 0.01082 0.63834
ITAC 29 4 110 26 0.01104 0.65159
TARC 248 59 478 112 0.02152 1.26942
IL8 61 4 456 151 0.02259 1.33290
IL4 00520 . 0 2 6 0 1 1 . 5 3 4 6 4
TNFa 521 65 610 59 0.02824 1.66587
Gro-A 314 146 1401 468 0.03637 2.14567
TIMP2 75277 5629 85674 4973 0.04508 2.65947
KGF 373 117 470 97 0.04513 2.66289
Soluble Factors (pg/ml) present in the serum of patients undergoing high dose IL-2 immunotherapy were averaged before and after 1 dose of IL-2. 
A paired 2-tailed student t test was used to assess significance with an arbitrary cutoff of p= 0.05. Bonferroni's correction was applied to the data 
set by correcting for a total of 59 soluble factors (IL-2 was not factored in); IL-2 levels were included as internal control (*) since these values 
reflect in part administered human recombinant IL-2.Journal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/17
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their proximity to each other taking into account the
entire data set. This unsupervised analysis separated indi-
vidual samples into three groups that matched the time of
collection. In fact, samples obtained before treatment,
those obtained after 1 dose and those after 4 grouped
together with the exception of the sample obtained from
patient 16 after the first dose that clustered with the pre-
treatment samples. Analysis of the three categories of sam-
ples suggested that soluble factors in serum of patients
treated with IL-2 belong to four categories according to
their pattern of expression. A first category demonstrated
a slight increase after the first dose and stabilized for the
duration of the study (Black bar, Figure 1). A second
group was characterized by an increase that occurred only
after the fourth dose (Blue bar, Figure 1). A third group
increased rapidly after one dose but concentrations
Table 5: Soluble factor (pg/ml) concentrations in the serum of 10 patients who completed the study (only factors that demonstrated 
significant changes in concentration after the 4th dose compared with before therapy are shown)
Soluble Factor Average before IL-2 STD error before IL-2 Average after 4 doses STD error after 4 doses p value before vs. after 
4 doses
Bonferroni 
correction
IL2* 0 0 1426 394 0.00410 0.24205
MCP2 32 9 296 34 0.00001 0.00047
I309 18 4 222 25 0.00001 0.00070
IP10 146 18 2940 390 0.00003 0.00178
VegF 865 131 1411 132 0.00003 0.00191
ITAC 29 4 438 57 0.00003 0.00200
TNFR1 1641 112 6067 651 0.00004 0.00207
IFNγ 149 21 246 16 0.00004 0.00234
IL15 0 0 14 2 0.00005 0.00269
MCP1 984 227 31267 4583 0.00006 0.00367
MIP3b 142 17 33836 5140 0.00007 0.00405
Lymph 111 22 639 95 0.00010 0.00571
E-Selectin 106029 5703 377934 40503 0.00011 0.00638
TARC 248 59 8993 1517 0.00015 0.00867
SDF1b 62 21 883 142 0.00018 0.01045
MMP8 1187 455 5081 927 0.00024 0.01406
MCP3 10 1 53 8 0.00029 0.01685
MDC 586 111 1272 214 0.00031 0.01841
Eotaxin 115 22 392 67 0.00032 0.01890
TIMP2 75277 5629 108359 4266 0.00033 0.01949
Exodus2 419 71 1108 157 0.00049 0.02911
MMP13 839 221 1742 171 0.00055 0.03224
TIMP1 198383 20136 1021646 178036 0.00071 0.04194
TNFa 521 65 839 74 0.00086 0.05090
MIP1b 512 205 4072 794 0.00105 0.06189
TNFR2 3195 259 16353 3113 0.00115 0.06774
HGF 8281 2359 17298 1311 0.00251 0.14822
IL5 0 0 40 10 0.00274 0.16167
MMP9 233004 43617 657077 142793 0.00391 0.23066
IL7 2 1 6 2 0.00508 0.29968
MMP2 210099 37913 399516 50101 0.00510 0.30111
MMP10 1467 220 3247 528 0.00545 0.32168
MCP4 84 19 1663 495 0.00698 0.41181
IL10 3 1 179 54 0.00707 0.41723
MIP3a 18 4 1346 414 0.00784 0.46274
IL6 50 5 608 184 0.01139 0.67211
VCAM1 310701 30008 1278753 336280 0.01248 0.73618
MMP3 27613 6960 59390 16227 0.01433 0.84561
KGF 373 117 505 109 0.01473 0.86914
ICAM1 499363 62669 2313052 682964 0.01505 0.88787
IL6R 23556 1882 19437 1316 0.02143 1.26450
IL4 0 0 5 2 0.02359 1.39181
IL8 61 4 296 90 0.02410 1.42202
IL18 67 11 167 43 0.03041 1.79442
IL16 13 6 104 43 0.04344 2.56278
MIP1a 2952 143 3160 156 0.05446 3.21343
Soluble Factors (pg/ml) present in the serum of patients undergoing high dose IL-2 immunotherapy were averaged before and after 4 doses of IL-2. 
A paired 2-tailed student t test was used to assess significance with an arbitrary cutoff of p = 0.05. Bonferroni's correction was applied to the data 
set by correcting for a total of 59 soluble factors (IL-2 was not factored in); IL-2 levels were included as internal control (*) since these values reflect 
in part administered human recombinant IL-2.Journal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/17
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decreased by the fourth dose (Orange bar, Figure 1).
Finally, a last group increased in concentration after the
first dose and progressively continued to increase after the
4th (Red bar, Figure 1).
The majority of changes in the circulating soluble factors
tested occurred after 4 doses of IL-2 (Blue bar Figure 1 and
Figure 2). In addition a large cluster of cytokines progres-
sively increased from before therapy throughout IL-2 ther-
apy (Figure 3). We observed several markers of systemic
and vascular inflammation whose exact function in vivo
remains to be elucidated (Figure 4). The soluble form of
adhesion molecules ICAM1, V-CAM, E selectin have been
reported to be similarly elevated in the serum of chronic
renal allograft rejection patients [22], multiple sclerosis
and Lupus (([23,24], coronary artery disease [25,26],
endothelial vasodilatation [27], immunotherapy of
tumor patients with TNF alpha [28] and immunotherapy
of melanoma patients with IL-12 [29] (Figure 5). Our
findings may suggest similarly to these reports not only
that circulating soluble adhesion molecules play a major
role in the inflammatory reaction induced during IL-2
administration [12] but that they may be associated to the
toxic effects of IL-2 (blood vessel inflammation, vascular
damage, leakage, hypotension).
Metalloproteinases (MMP) 2, 3, 10, 13, tissue inhibitor of
metalloproteinase (TIMP1), macrophage derived chemo-
attractant (MDC) and thymus and activation regulated
chemokine (TARC), Lymphotactin, secondary lymphoid
tissue chemokine (Exodus2), and interferon inducible T
cell alpha chemo-attractant (I-TAC) were also on average
increased after 4 doses of IL-2. The presence of high levels
of MMP is in line with the inflammatory process previ-
ously described by us at the genomic level [12] and gen-
eral outburst of cytokines following IL-2 stimulation. In
Table 6: Soluble factor (pg/ml) concentrations in the serum of 10 patients who completed the study (only factors that demonstrated 
significant changes in concentration between the 1st and 4th dose are shown)
Soluble Factor Average 
before IL-2
STD error 
before Il-2
Average after 
1 dose
STD error 
after 1 dose
Average after 
4 doses
STD error 
after 4 doses
pvalue after 1 
vs after 4 doses
Bonferroni 
correction
I309 18 4 52 8 222 25 0.00004 0.00232
MIP3b 18 4 347 51 33836 5140 0.00007 0.00414
TARC 248 59 478 112 8993 1517 0.00015 0.00882
E-Selectin 106029 5703 118981 5972 377934 40503 0.00018 0.01034
Exodus2 419 71 307 26 1108 157 0.00028 0.01628
MDC 586 111 644 109 1272 214 0.00029 0.01740
ITAC 29 4 110 26 438 57 0.00033 0.01935
Lymph 111 22 259 39 639 95 0.00083 0.04905
MCP3 10 1 17 2 53 8 0.00101 0.05956
TIMP1 198383 20136 242215 25530 1021646 178036 0.00116 0.06856
HGF 8281 2359 10836 1791 17298 1311 0.00148 0.08712
IL15 0 0 6 2 14 2 0.00148 0.08719
MMP13 839 221 1081 251 1742 171 0.00163 0.09604
MCP2 32 9 1500 291 296 34 0.00174 0.10287
MIP1b 512 205 30149 6560 4072 794 0.00180 0.10631
TNFR2 3195 259 6014 628 16353 3113 0.00221 0.13028
TNFa 521 65 610 59 839 74 0.00281 0.16587
MCP1 984 227 81270 13486 31267 4583 0.00447 0.26392
NAP2 9479881 2329514 10970212 2240959 8251596 2122243 0.00482 0.28444
IL5 0 0 8 2 40 10 0.00564 0.33291
MMP8 1187 455 3340 500 5081 927 0.00852 0.50244
MMP2 210099 37913 201099 41748 399516 50101 0.00889 0.52449
MCP4 84 19 264 71 1663 495 0.00932 0.54966
IL6R 23556 1882 26254 3045 19437 1316 0.01011 0.59636
ICAM1 499363 62669 501688 90740 2313052 682964 0.01143 0.67431
MMP3 27613 6960 24603 5418 59390 16227 0.01149 0.67778
MMP10 1467 220 1694 218 3247 528 0.01209 0.71314
TIMP2 75277 5629 85674 4973 108359 4266 0.01334 0.78706
VCAM1 310701 30008 335385 17713 1278753 336280 0.01469 0.86698
IP10 146 18 1571 273 2940 390 0.01571 0.92712
IL10 3 1 45 23 179 54 0.02652 1.56497
IL18 67 11 93 19 167 43 0.03116 1.83873
TNFR1 1641 112 4702 512 6067 651 0.03126 1.84407
IL16 13 6 19 11 104 43 0.04434 2.61591
Rantes 40861 10853 56208 8799 34797 6495 0.04881 2.87988
Soluble Factors levels were averaged across 10 patients after 1 and 4 doses of IL-2. A paired 2-tailed student t test was used to assess significance 
with an arbitrary cutoff of p= 0.05. Bonferroni's correction was applied to the data set by correcting for a total of 59 soluble factors.Journal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/17
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fact, MMP are involved in matrix destruction and regener-
ation, mononuclear phagocyte migration and function as
regulatory proteins by promoting the activation and/or
degradation of cytokines. High serum levels of MMP 2
and 9 have been reported in inflammatory diseases of the
central nervous system and in particular in MS patients
and play a leading role in the evolution of demyelinating
lesions(([23]. We could thus hypothesize that the
presence of high levels of circulating MMP following IL-2
therapy (after 1 and 4 doses) may be responsible for
destruction of endothelial basement membranes, extrava-
sation of mononuclear cells and more generally accumu-
lation of toxic byproducts (Figure 4). In addition, it
Unsupervised Hierarchical clustering (Kendall's Tau) of serum samples from RCC patients obtained before, after 1 and 4 doses  of IL-2 (720,000 IU/kg) Figure 1
Unsupervised Hierarchical clustering (Kendall's Tau) of serum samples from RCC patients obtained before, 
after 1 and 4 doses of IL-2 (720,000 IU/kg). Hierarchical clustering [21] was applied to the data set encompassing 46 
cytokines significantly expressed (excluding IL-2) between before and after 4 doses of IL-2 across 10 serum samples 
(P2,3,4,5,9,12,13,14,15,16) obtained before, after 1 and after 4 doses of IL-2 (720,000 IU/kg). Values corresponding to soluble 
factors concentration in pg/ml were transformed in natural log (LN) values, average corrected across experimental samples 
and displayed according to the central method for display using a normalization factor as recommended by Ross [33]. Patients' 
serum samples clustered according to the three time points of IL-2 administration. Expression of soluble factors segregated in 
4 distinct kinetic profiling. Black bar = soluble factor minimally changing from before to after 4 doses; blue bar = soluble factor 
expression enhanced at 4 doses only; orange bar = soluble factor expression enhanced after 1 dose; red bar = soluble factor 
expression enhanced at 1 and 4 doses.
0
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suggests a key involvement of mononuclear phagocytes
activation in the IL-2-induced inflammatory process [12]
since these cells are major producers of MMPs.
Interestingly, tissue inhibitor of metalloproteinase
(TIMP1) was also highly expressed after 4 doses. Although
the concomitant presence of MMP2 and TIMP1 is not sur-
prising since TIMP1 is the natural inhibitor of MMP2 and
MMP9 (which we find particularly increased after 1 and 4
doses), the concurrent dramatic increase of these two fac-
tors may reflect an inhibitory feed back mechanism
limiting the magnitude of IL-2 induced inflammation. It
is also possible that TIMP1 at such high doses may
increase cell proliferation and metabolic activity as previ-
ously reported [30].
Elevated MDC and TARC, Lymphotactin, Exodus2 and I-
TAC supports the presence of a strong migration signal for
monocytes, NK cells and T cells as described by us at the
RNA level [12] and of a potent mobilization of innate and
acquired mechanisms of immune defense. Among the
soluble factors that increased significantly after 1 dose and
either remained elevated or increased further in
concentration after 4 doses (Figure 1 Red bar), were a
group of potent inflammatory chemo-attractants for
monocytes and lymphocytes (MCP-1, MIP-3, IP-10, I-
Soluble factors increasing after 4 doses of IL-2 Figure 2
Soluble factors increasing after 4 doses of IL-2 Soluble factors increasing after 4 doses of IL-2 clustered in figure 1(blue 
bar), were averaged across 10 patients. Values represent concentrations in (pg/ml) ± SD.
0.E+00 1.E+06 2.E+06 3.E+06 4.E+06
IL15
IL5
MCP3
IL16
IL18
IL10
ITAC
Lymph
Exodus2
MDC
MCP4
MMP13
MMP10
TARC
TNFR2
MIP3b
MMP3
TIMP2
E-Selectin
MMP2
TIMP1
VCAM1
ICAM1
Average post 4
average post1
Average pre
0 10000 20000 30000 40000 50000 60000 70000 80000
MMP10
TARC
TNFR2
MIP3b
MMP3
0 500 1000 1500 2000 2500
IL15
IL5
MCP3
IL16
IL18
IL10
ITAC
Lymph
Exodus2
MDC
MCP4
MMP13
4
pg/mlJournal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/17
Page 10 of 14
(page number not for citation purposes)
309, stromal derived factor (SDF1)), eosinophils
(eotaxin), the soluble TNF R1, the cytokines IL-6, 7 and 8.
The high concentrations of soluble TNFR1 in patients
undergoing IL-2 therapy are very striking. Circulating lev-
els of TNF-α and sTNFRI have been reported to be signifi-
cantly increased in rheumatoid arthritis patients with
amyloidosis as those without [31] (Figure 4) and after IL-
2 therapy [34] (Figure 5). Thus this soluble receptor may
be yet another important player in enhancing the overall
IL-2 inflammatory process. The persistence/increase of
these factors throughout the first 24 hours of IL-2 admin-
istration (1–4 doses) may suggest that these early
response proteins are the true initiator of many of the IL-
2 immune enhancing effects. On the other hand, sus-
tained release/accumulation may be the results of soluble
receptor saturation and the initiation of a cascade of toxic
byproducts.
An additional finding was the identification of two sub-
groups of patients who seemed to produce different
amount of cytokines in response to IL-2; a smaller group
(including patient 9, 13 and 16) appeared to produce less
cytokines compared with other patients. This is a finding
similar to what was previously noted in a small in vitro
analysis of PBMC stimulated with IL-2 [15]. This finding
if corroborated by larger patient series may have
Soluble factors increasing after 1 and 4 doses of IL-2 Figure 3
Soluble factors increasing after 1 and 4 doses of IL-2 Soluble factors increasing after 1 and 4 doses of IL-2 clustered in 
figure 1(red bar), were averaged across 10 patients. Values represent concentrations in (pg/ml) ± SD.
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important implications in separating patients who
respond or do not respond to therapy.
The number of patients tested was too small to correlate
patterns of expression of various factors with the toxicity
experienced or the clinical outcome of their treatment
(data not shown).
In summary, this pilot study identified different patterns
of production of cytokines during IL-2 therapy that may
be of relevance to clinical outcome and toxicity if studied
in larger patient populations. In addition, patients' varia-
bility was noted with some patients appearing to be more
prone to produce cytokines in response to IL-2. Immune
polymorphism(s) affecting individual responses to
immune stimulation could be at the basis of this phenom-
enon [32]. Therefore, further studies should include not
only collection of serum samples for serum analysis but
also of DNA for genetic analysis. Based on this analysis,
we propose a prospective collection of serum samples in a
larger cohort of patients undergoing IL-2 administration
with the purpose of discerning patterns predictive of clin-
ical outcome and toxicity.
Soluble Adhesion molecules in serum as markers of systemic and vascular inflammation: correlation with high dose IL-2 immu- notherapy and other inflammatory diseases Figure 4
Soluble Adhesion molecules in serum as markers of systemic and vascular inflammation: correlation with high 
dose IL-2 immunotherapy and other inflammatory diseases. Increased levels of soluble adhesion molecules (sICAM, 
sVCAM, sV-Selectin, sTNFRI) and metalloproteinases (MMP2, MMP9) have been described in a variety of inflammatory dis-
eases and believed to act as markers of endothelial cell (EC) activation. Potential explanation for IL-2 effects and toxicity in 
relation to the effects noted in the reported inflammatory diseases, are listed on the right of this panel.
sICAM-1
sVCAM
sE-selectin
IL-6
IL-8
MCP-1 ( Boratynska Arch Med Wewn, 1998)
Chronic renal graft rejection
Multiple sclerosis
Inflammatory
demyelinating disease 
recruitment of lymphocytes 
and macrophages across 
endothelial cells (EC) of blood 
brain barrier (BBB) essential 
step in initiation of CNS 
inflammation
sICAM-1
sVCAM
sE-selectin
MMP2
MMP9
Cell migration through BBB into 
CNS involves destruction of the 
subendothelial basement 
membrane. This process is 
mediated by MMP
(Correale et al, J of Neuro immunol,2003)
Coronary artery disease sICAM-1
sVCAM
sE-selectin Endothelial vasodilatory
function in healthy individuals
(Blankenberg et al., circulation, 2001)
(Hajilooi et al., Immunol Invest, 2003)
(Holmlund et al Atherosclerosis, 2002)
Potential  explanation for
IL-2  effects / toxicity
Tumor rejection
Destruction of the 
endothelial basement 
membrane,
tissue damage,
extravasation of 
mononuclear cells
Leakage hypotension
Blood vessel inflammation
Vascular damage
Uveitis
sICAM-1 (Marcos Martic Current Eye Res, 2000)
Rheumatoid arthritis sTNFR1 (Maury et al., Arthritis Rheum 2003 )Journal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/17
Page 12 of 14
(page number not for citation purposes)
Materials and Methods
Patients
Sixteen patients with metastatic RCC were recruited at the
Carolinas Medical Center (Charlotte, NC 28203) to
receive standard high-dose (720,000 IU/Kg) IL-2 (Pro-
leukin, Chiron, Emeryville, CA). Serum was collected
prior to treatment from the 16 patients, three hours after
the first dose in 15 patients and 3 hours after the first and
the fourth dose in 10 patients (Table 1). Toxicities and
laboratory abnormalities are reported according to the
CMC common toxicity criteria in Table 2.
Serum collection
Fifty to 60 ml of peripheral blood were collected at the
bedside in BD Vacutainer™ plus (plastic) serum tubes (BD
cat # 367820) before (Pre) and 3–4 hours after 1 (1D) and
4 (4D) doses of IL-2. The complete collection was success-
ful in 10 individuals. Pre and 1D collections were
obtained from an additional 5 patients. Serum was imme-
diately separated to avoid protein degradation, stored
upright for 10 minutes and centrifuged at room
temperature in a horizontal rotor at 3,500 rpm for 8 min-
utes. The serum phase was then transferred to a 50 ml con-
ical tube (BD, falcon # 352098) pooling serum from 2 to
Soluble Adhesion molecules in serum as markers of systemic and vascular inflammation: correlation with high dose IL-2 immu- notherapy and other therapies Figure 5
Soluble Adhesion molecules in serum as markers of systemic and vascular inflammation: correlation with high 
dose IL-2 immunotherapy and other therapies. The presence of increased expression of soluble adhesion molecules 
(sICAM, sVCAM, sV-Selectin) detected in our study, have also been reported in the serum of patients undergoing TNF alpha 
and IL-12 immunotherapy. Furthermore, increased level of the inflammatory cytokines (IL-8, IL-6) and soluble TNF receptor 
(sTNFRI) confirmed previous findings in patients receiving high dose immunotherapy with IL-2.
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3 separator tubes and subsequently aliquoted (1 ml/vial)
in cryogenic vials (Nunc cat #363401, St Pleasant Prairie,
WI). Serum aliquots were snap frozen in dry ice and
stored at -80°C until use.
Protein platforms
Protein serum levels were assessed on protein-based plat-
forms (Pierce SearchLight Proteome Arrays, Boston, MA).
These arrays consist of multiplexed assays that measure 16
or more proteins per well in standard 96 well plates. The
arrays are produced by spotting a 2 × 2, 3 × 3 or 4 × 4 pat-
terns of different monoclonal antibodies into each of a
96-well plate. Following a typical sandwich ELISA proce-
dure, signal is generated using a chemiluminescent sub-
strate. The light produced at each spot in the array is
captured by imaging the entire plate with a commercially
available cooled CCD camera. The data are reduced using
image analysis software that calculates exact values (pg/
ml) based on standard curves. Each sample was tested for
the following 68 human proteins: monocyte inhibitory
protein (MIP)-1α; MIP-1β; monocyte chemotactic protein
(MCP)-1/CCL1; MCP-2/CCL8; MCP-3/CCL7; MCP-4/
CCL13; macrophage inflammatory protein (MIP)-3β /
CCL19; MIP-3α /CCL20; exodus2/CCL21(similar to
MIP3α); thymus and activation regulated chemokine
(TARC/CCL17); I-309/CCL1; eotaxin/CCL11; macro-
phage derived chemo-attractant (MDC/CCL22); inter-
feron inducible protein 10 (IP10/CXCL10); stromal
derived factor (SDF1)-beta; lymphotactin/XCL1; leuko-
cyte Inhibitory factor (LIF); rantes/CCL5; monokine
induced by gamma interferon (MIG/CXCL9); ITAC;
TNFα; IFNγ; IFNa; GM-CSF; ENA-78/CXCL5; Gro-A/
CXCL1; neutrophil activating protein (NAP)-2/CXCB7;
vascular endothelial growth factor (VEGF); angiotensin
(Angio)-2; ciliary neuronotrophic factor (CNTF); fibrob-
last growth factor (FGF)-basic; keratinocyte growth factor
(KGF); hematopoietic growth factor (HGF); heparin bind-
ing epidermal growth factor (HB-EGF); platelet derived
growth factor PDGF-BB; thymopoietin (Tpo); tissue
inhibitor of metalloproteinases (TIMP)1; TIMP2; matrix-
metalloproteinase (MMP)-1; MMP-2; MMP-3; MMP-8;
MMP-9; MMP-10; MMP-13; interleukin (IL)-1α; IL-1β; IL-
2; IL-4; IL-5; IL-6; IL-7; IL-8; IL-9; IL-10; IL-12p70; IL-13;
IL-12p40; IL-15; IL-16; IL-18; tumor necrosis factor recep-
tor (TNFR)-1; TNFR2, interleukin-6 receptor (IL-6R);
ICAM1; VCAM1; E-Selectin/CD62E; L-Selectin/ CD62L.
Statistical analysis
Eight of these factors (LIF, IFNα, GM-CSF, IL-1α, IL-1β, IL-
9, IL-12p70, IL-13), were found to be below the limit of
detection in all conditions tested and were removed from
the data set prior to statistical analysis because we could
not determine with certainty whether changes in their
expression occurred below such a threshold. Paired two
tailed t test was used to determine the level of significance
in serum concentration changes for the remaining 60
soluble factors at different time points. IL-2 was included
in the analysis as an internal control. Differences were
considered significant at an arbitrary cut off p2-value of ≤
0.05. Significance was also assessed after correction for the
number of tests performed applying the Bonferroni's cor-
rection to 59 soluble factors (IL-2 was not considered
among the tested variables since it was not possible to dis-
cern the respective contribution to serum concentration of
exogenously administered or endogenously secreted IL-
2).
Relatedness in cytokine expression patterns at different
time points of IL-2 treatment was tested with unsuper-
vised by applying Eisen's hierarchical clustering methods
[21] to the data set encompassing the 45 cytokines and the
10 samples (P2,3,4,5,9,12,13,14,15,16, Figure 1). This
tool ranks experiments according to their proximity to
each other taking into account the entire data set.
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